๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD
NCT07665359Chronic Obstructive Pulmonary Disease (COPD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Not yet open
Analysis of the Effectiveness and Safety of RIRS Under Local Anesthesia and Its Influencing Factors
NCT06737497Urolithiasis
The First Affiliated Hospital of Guangzhou Medical University
Observational
100
Guangzhou
2026-07-01
Recruiting
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT07693881EBV Infection After Allogenic HSCT
Nanfang Hospital, Southern Medical University
Not applicable
106
Guangzhou
2026-07-01
Not yet open
New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes
NCT07635953Diabetes Mellitus
Sun Yat-sen University
Phase 3
296
Guangzhou
2026-07-01
Recruiting
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
NCT07658833Hepatocellular Carcinoma (HCC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
120
Guangzhou
2026-07-01
Not yet open
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities
NCT07630077Non Small Cell Lung Cancer
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-07-01
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Not yet open
Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma
NCT07654465Marginal Zone Lymphoma(MZL)
Sun Yat-sen University
Phase 2
144
Guangzhou
2026-07
By invitation
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Bietti Crystalline Corneoretinal Dystrophy
Chigenovo Co., Ltd
Not applicable
32
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2026-07
Not yet open
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
NCT07696091Non-cystic Fibrosis Bronchiectasisใ€Chronic Sinusitis Without Nasal Polypsใ€Chronic Obstructive Pulmonary Disease
Reistone Biopharma Company Limited
Phase 1
40
Guangzhou
2026-07
Not yet open
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
NCT07738679Advanced Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
Multicenter Prospective Validation of AI Models for Malignancy Risk Prediction in Pulmonary Nodules
NCT07727122Pulmonary Nodules
Guangdong Provincial People's Hospital
Observational
3,000
Chongqing, Guangzhou, Xuzhou, Hangzhou
2026-07
Not yet open
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515Intrahepatic Cholangiocarcinoma (Icc)
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Nanchang, Qingdao, Chengdu
2026-07
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
NCT07473726Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1
72
Guangzhou, Hongkou, Taiyuan
2026-06-30
Not yet open
Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye
NCT07679685Dry Eye
Beijing Tongren Hospital
Phase 4
159
Beijing, Guangzhou, Shanghai, Xi'an, Zhongshan
2026-06-30
Not yet open
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
NCT07601334Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
Phase 1
45
Guangzhou
2026-06-30
Recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
Pfizer
Phase 2
120
Beijing, Guangzhou, Jinan
2026-06-30
Recruiting
AMT-116 in Combination With AK112 in Patients With Lung Cancer
NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC)
Multitude Therapeutics Inc.
Phase 1/2
118
Guangzhou, Hangzhou
2026-06-29
Recruiting
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
NCT07667803Weight Management
AstraZeneca
Phase 3
4,500
Binzhou, Chengdu, Deyang, Ganzhou, Guangzhou, Haikou, Hangzhou, Huaian
2026-06-29
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT001 Following Intravenous Administration in Participants With Chronic Spontaneous Urticaria (CSU)
NCT07717905Chronic Spontaneous Urticaria
Bambusa Therapeutics
Phase 1/2
48
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jinzhou, Wuxi, Taiyuan, Xiโ€™an
2026-06-29
Not yet open
A Phase โ…ข Clinical Study of SNA02-48 Injection
NCT07633119Tetanus
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Not yet open
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT07658352B-Cell Non-Hodgkin Lymphoma
Shanghai Helioson Pharmaceutical Co., Ltd.
Phase 1/2
114
Guangzhou
2026-06-26
Recruiting
Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab
NCT07039422Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia
Novartis Pharmaceuticals
Phase 2
60
Guangzhou, Dalian, Tianjin
2026-06-26
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766Platinum-resistant Ovarian Cancer
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07570017DLBCL
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
42
Guangzhou, Shanghai
2026-06-25
Active, closed
Safety and Food Effect on Single-Dose Bioavailability of F-02-2-Na in Healthy Adult Subjects
NCT07346027Hyperuricemia With or Without Gout
Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
Phase 1
12
Guangzhou
2026-06-25
Recruiting
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
NCT07754812NSCLC (Non-small Cell Lung Cancer)
Shanghai Pulmonary Hospital, Shanghai, China
Phase 4
78
Guangzhou, Suqian, Shanghai, Hangzhou, Lishui
2026-06-25
Recruiting
Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer
NCT07674732Short-course Radiotherapy Plus Chemotherapy, Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab
Dechang Diao
Phase 2
76
Guangzhou
2026-06-24
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
Hoffmann-La Roche
Phase 3
380
Guangzhou, Nanjing, Qingdao, Kunming, Hangzhou, Jinan, Nanning, Shanghai
2026-06-23
Recruiting
Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
NCT07604311IgA Nephropathy (IgAN)
Nanfang Hospital, Southern Medical University
Phase 4
288
Guangzhou
2026-06-23
Recruiting
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
NCT07775950Colorectal Cancer (MSI-H), Molecular Residual Disease
Sun Yat-sen University
Not applicable
100
Guangzhou
2026-06-23
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892Systemic Lupus Erythematosus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
198
Bengbu, Bozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Jiangmen, Shenzhen
2026-06-22
Recruiting
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
NCT07380113Pruritus Chronic, Kidney Diseases, Chronic, Renal Insufficiency, Chronic, Uremia; Chronic
Zhujiang Hospital
Phase 4
50
Guangzhou
2026-06-22
Not yet open
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
NCT07657273Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
20
Guangzhou
2026-06-22
Not yet open
Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
NCT07565415Hepatocellular Carcinoma (HCC), Cachexia, Anorexia, Malnutrition
Nanfang Hospital, Southern Medical University
Phase 2
88
Guangzhou
2026-06-22
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
NCT07551427Myelofibrosis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
51
Hefei, Fuzhou, Guangzhou, Nanning, Cangzhou, Chengde, Shijiazhuang, Xingtai
2026-06-18
Not yet open
A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT)
NCT07579949Thalassemia
ScinnoHub Pharmaceutical Co., Ltd.
Phase 2
30
Foshan, Guangzhou, Maoming, Liuzhou, Nanning, Haikou, Chengdu
2026-06-18
Recruiting
Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
NCT07653958Pulmonary Hypertension, Pulmonary Hypertension Crisis
Peking Union Medical College Hospital
Observational
5,000
Guangzhou, Kunming, Beijing, Shanghai
2026-06-17
Recruiting
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
NCT07781124End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Recruiting
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07638436Esophageal Squamous Cell Carcinoma (ESCC)
Sun Yat-sen University
Phase 2
42
Guangzhou
2026-06-17
Recruiting
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
NCT07726953Acute Respiratory Distress Syndrome
Southeast University, China
Not applicable
500
Beijing, Changchun, Chengdu, Chenzhou, Dalian, Fuzhou, Guangzhou, Hangzhou
2026-06-16
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Changchun, Jinan, Yantai
2026-06-16
Recruiting
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
NCT07637877Immunological Non-Responders in People With HIV
Beijing 302 Hospital
Phase 2
21
Beijing, Guangzhou, Shenzhen
2026-06-15
Recruiting
CLE vs. ROSE for Ex Vivo Lung Biopsy Assessment
NCT07725510Peripheral Pulmonary Lesions (PPLs)
Guangzhou Medical University
Observational
30
Guangzhou
2026-06-15
Recruiting
Efficacy and Safety of Probiotics for Anxiety Depression
NCT07331987Anxiety Depression
Moon (Guangzhou) Biotechnology Co., Ltd.
Not applicable
60
Guangzhou
2026-06-15
Recruiting
Effectiveness and Safety of the Ultheraยฎ System for Skin Laxity in the Lower Face, Submentum and Neck
NCT07614997Cutis Laxa
Merz North America, Inc.
Not applicable
218
Beijing, Guangzhou, Nanjing, Xi'an, Shanghai
2026-06-15
Not yet open
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
NCT07636486Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
Nanfang Hospital, Southern Medical University
Phase 2/3
90
Guangzhou
2026-06-15
Recruiting
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC
NCT07645222Lung Cancer
Hansoh BioMedical R&D Company
Phase 1
396
Guangzhou
2026-06-15
Not yet open
A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer
NCT07652073Advanced or Metastatic Ovarian Cancer
Danatlas Pharmaceuticals Co., Ltd
Phase 2
30
Guangzhou, Beijing
2026-06-15
Recruiting
SGRT in Head and Neck Cancer Radiotherapy
NCT07726407Head and Neck Cancer, Radiotherapy, Conformal (IMRT)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
40
Guangzhou
2026-06-15
Recruiting
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
NCT07606937Relapsed/Refractory Large B-cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase EARLY_PHASE1
12
Beijing, Guangzhou, Suzhou, Shanghai, Chengdu, Tianjin
2026-06-12
Active, closed
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898Severe Hemophilia A
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Guangzhou, Hefei, Jinan, Kunming, Nanning
2026-06-12
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
NCT07692165Ulcerative Colitis (UC)
Innatus Therapeutics (Shanghai) Co., Ltd.
Phase 1/2
24
Guangzhou, Shenyang, Beijing, Hangzhou, Shanghai, Taiyuan, Weifang, Wenzhou
2026-06-11
Active, closed
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca
Phase 2
326
Beijing, Changsha, Chongqing, Guangzhou, Hangzhou
2026-06-11
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248Primary Immune Thrombocytopenia
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
Xicheng, Guangzhou, Zhenzhou
2026-06-11
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT07606612Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
31
Guangzhou
2026-06-11
Recruiting
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
NCT07516184Suspected Asthma
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Recruiting
A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
NCT07641426Antibody Mediated Rejection
CASI pharmaceuticals, Inc.
Phase 1/2
58
Beijing, Guangzhou, Wuhan, Xi'an
2026-06-09
Recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
Phase 1/2
40
Guangzhou, Changsha
2026-06-08
Recruiting
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
NCT07543536Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Sun Yat-sen University
Phase 3
132
Guangzhou
2026-06-08
Recruiting
A Study to Evaluate AHB-137 Injection in Treatment-naรฏve Participants With Chronic Hepatitis B
NCT07635186Chronic Hepatitis B
Ausper Biopharma Co., Ltd.
Phase 2
320
Beijing, Chongqing, Xiamen, Guangzhou, Jiangmen, Meizhou, Qingyuan, Shenzhen
2026-06-05
Recruiting
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07544056Locally Advanced Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer
BeBetter Med Inc
Phase 2/3
446
Guangzhou, Changsha
2026-06-04
Recruiting
Modified Single-Incision Plus One-Port Versus Conventional Five-Port Laparoscopic Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas
NCT07744087Ampullary Carcinoma, Duodenal Adenocarcinoma, Distal Cholangiocarcinoma
Nanfang Hospital, Southern Medical University
Not applicable
232
Chongqing, Guangzhou, Chengdu, Jiancheng
2026-06-04
Recruiting
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
NCT07486817Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim
Phase 2
60
Guangzhou, Shanghai
2026-06-04
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
NCT07633301Narcolepsy Type 1
Takeda
Phase 2
92
Beijing, Guangzhou, Zhengzhou
2026-06-04
Not yet open
Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)
NCT07581782Neovascular Age-related Macular Degeneration(nAMD)
Sun Yat-sen University
Observational
50
Guangzhou
2026-06-01
Recruiting
Efficacy of Visual and Perceptual Training on Visual Function for Operative Congenital Ectopia Lentis Children
NCT07096622Ectopia Lentis, Lens Subluxation or Dislocation
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
82
Guangzhou, Qingyuan
2026-06-01
Not yet open
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
NCT07559929Small Cell Lung Cancer
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1/2
200
Guangzhou
2026-06-01
Recruiting
Luspatercept for CIA in AML
NCT07663864Chemotherapy-inducing Anemia
Guangdong Second Provincial General Hospital
Phase 1/2
40
Guangzhou
2026-06-01
Not yet open
Integrated Ultrasound-Derived Fat Fraction and 2D/4D HeartAI for Cardiovascular Risk Management in Patients With MASLD
NCT07545343MASLD, Cardiovascular (CV) Risk, Subclinical Cardiovascular Impairments
First Affiliated Hospital, Sun Yat-Sen University
Observational
700
Guangzhou
2026-06-01
Not yet open
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
NCT07621497Metastatic Colorectal Cancer (CRC)
Sun Yat-sen University
Phase 2
229
Guangzhou
2026-06-01
Not yet open
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
NCT07542912Complete Remission Rate๏ผŒ CRR, Progression Free Survival, Overall Survival, Adverse Event
Sun Yat-sen University
Not applicable
30
Guangzhou
2026-06-01
Not yet open
Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial
NCT07657169Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis, Molecular Typing
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
160
Guangzhou, Shenzhen, Jinan, Qingdao
2026-06-01
Not yet open
Comparing Efficacy and Safety of Enlituoยฎ Versus Erbituxยฎ Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
NCT07595276Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3
608
Guangzhou
2026-06-01
Recruiting
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
NCT07609121NSCLC (Non-small Cell Lung Cancer)
Sun Yat-sen University
Phase 2
160
Guangzhou
2026-06-01
Not yet open
Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma
NCT07616141Adenoid Cystic Carcinoma
Eye & ENT Hospital of Fudan University
Phase 2
76
Beijing, Guangzhou, Qingdao, Shanghai
2026-06-01
Not yet open
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
NCT07381309CRC, Liver Metastasis Colon Cancer
Jun Huang
Phase 2
114
Guangzhou
2026-06-01
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
NCT07610798Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
178
Guangzhou
2026-06-01
Not yet open
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT07612137Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
282
Guangzhou
2026-06-01
Recruiting
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
NCT07489573Hidradenitis Suppurativa (HS)
Novartis Pharmaceuticals
Phase 4
36
Guangzhou, Shijiazhuang, Chengdu, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2026-06-01
Not yet open
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
NCT07539753Breast Cancer, Brain Metastases, HR+/HER2- Breast Cancer
Nanfang Hospital, Southern Medical University
Phase 2
46
Guangzhou
2026-06-01
Not yet open
Spectral Precise Image-Colon Cancer
NCT07620444Colon Cancer Patients
Philips Clinical & Medical Affairs Global
Observational
100
Guangzhou
2026-06-01
Not yet open
Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07603349Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
Phase 2/3
405
Guangzhou
2026-06
Not yet open
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07630103Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
100
Guangzhou
2026-06
Not yet open
AI-Assisted Structured Guidance for Narrative Review Writing
NCT07618819AI-Assisted Academic Writing, Medical Education, Narrative Review Writing
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
102
Guangzhou
2026-06
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
NCT07622784Relapsed or Refractory B-cell Lymphoma
Sun Yat-sen University
Phase 2
20
Guangzhou
2026-06
Not yet open
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
260
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Zhanjiang, Nanning
2026-06
Not yet open
Treatment of Recurrent/Metastatic Head and Neck Cancer
NCT07601204Recurrent/Metastatic Head and Neck Cancer
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
128
Beijing, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Taiyuan, Chengdu
2026-06
Not yet open
Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis
NCT07650942Ulcerative Colitis (UC)
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
360
Guangzhou
2026-06
Not yet open
Sintilimab Plus FOLFIRI as Second-line Therapy for Patients With HER2-negative Advanced Gastric Cancer
NCT06365008Unresectable/Metastatic Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
27
Guangzhou
2026-06
Not yet open
Vasopressor Agents in Pulmonary Hypertension Crisis
NCT07667829Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Hypertension, Pulmonary
China National Center for Cardiovascular Diseases
Not applicable
75
Beijing, Guangzhou, Wuhan
2026-06
Recruiting
Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for Injection
NCT07729839Healthy Adult Participants
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Phase 1
34
Guangzhou
2026-05-31
Not yet open
Phase III Clinical Trial of Changji'an Capsules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver-Qi Invading Spleen Syndrome)
NCT07610434IBS, Diarrhea Predominant
Beijing Hospital of Traditional Chinese Medicine
Phase 3
636
Beijing, Chengdu, Chongqing, Guangzhou, Guizhou, Haozhou, Hebei, Heilongjiang
2026-05-31
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Rows per page Showing 201–300 of 3318
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=3

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.